Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification

Journal of Clinical Microbiology

Volumn 48, Issue 4, 2010, Pages 1161-1168

  Ross, R S ^a   Viazov, S ^a   Salloum, S ^a   Hilgard, P ^a   Gerken, G ^a   Roggendorf, M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CILUPREVIR; HEPATITIS ANTIGEN; HEPATITIS C ANTIGEN; HEPATITIS C VIRUS CORE ANTIGEN; PEGINTERFERON ALPHA; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIGEN DETECTION; ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; DIAGNOSTIC ACCURACY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; VIRUS REPLICATION;

ANTIGENS, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL CORE PROTEINS;

HEPATITIS C VIRUS;

EID: 77950506807     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01640-09     Document Type: Article

References (47)

1. Aoyagy, K., C. Ohue, K. Iida, T. Kimura, E. Tanaka, K. Kiyosawa, and S. Yagi. 1999. Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen. J. Clin. Microbiol. 37:1802-1808.
2. Bablok, W. 1993. Range of linearity, p. 251-258. In R. Haeckel (ed.), Evaluation methods in laboratory medicine. VHC, Weinheim, Germany.
3. Blatt, L. M., M. G. Mutchnik, M. J. Tong, F. M. Klion, E. Lebovics, B. Freilich, N. Bach, C. Smith, J. Herrera, H. Tobias, A. Conrad, P. Schmid, and J. G. McHutchinson. 2000. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J. Viral Hepat. 7:196-202.
4. 4. Bouvier-Alias, M., K. Patel, H. Dahari, S. Beaucourt, P. Larderie, L. Blatt, C. Hezode, G. Picchio, D. Dhumeaux, A. U. Neumann, J. G. McHutchinson, and J.-M. Pawlotsky. 2002. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 36:211-218. (Pubitemid 34700780)
5. Bouzgarrou, N., I. Fodha, S. Ben Othman, A. Achour, F. Grattard, A. Trabelsi, and B. Pozzetto. 2005. Evaluation of a total core antigen assay for the diagnosis of hepatitis C virus infection in hemodialysis patients. J. Med. Virol. 77:502-508.
6. 6. Cagnon, L., P. Wagaman, R. Bartenschlager, T. Pietschmann, T. Gao, N. M. Kneteman, D. L. J. Tyrell, C. Bahl, P. Niven, S. Lee, and K. A. Simmen. 2004. Application of the trak-C™ HCV core assay for monitoring antiviral activity in HCV replication systems. J. Virol. Methods 118:23-31. (Pubitemid 38648771)
7. Centers for Disease Control and Prevention. 2001. Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR Recomm. Rep. 50(RR-5):1-43.
8. Chapko, M. K., K. L. Sloan, J. W. Davison, D. R. Dufour, D. D. Bankson, M. Rigsby, J. A. Dominitz, and the Hepatitis C Resource Center Program, Department of Veterans Affairs. 2005. Cost effectiveness of testing strategies for chronic hepatitis C. Am. J. Gastroenterol. 100:607-615.
9. Chevaliez, S., and J.-M. Pawlotsky. 2005. Use of virological assays in the diagnosis and management of hepatitis C virus infection. Clin. Liver Dis. 9:371-382.
10. Dickson, R. C., M. Mizokami, E. Orito, K. P. Qian, and J. Y. Lau. 1999. Quantification of serum HCV core antigen by a fluorescent enzyme immunoassay in liver transplant recipients with recurrent hepatitis C. Clinical and virologic implications. Transplantation 68:1512-1516.
11. Fabrizi, F., A. F. De Vecchi, G. Como, G. G. Lunghi, and P. Martin. 2005. De novo HCV infection among dialysis patients: a prospective study by HCV core antigen ELISA assay. Aliment. Pharmacol. Ther. 21:861-869.
12. 12. Glynn, S. A., D. J. Wright, S. H. Kleinman, D. Hirschkorn, Y. Tu, C. Heldebrandt, R. Smith, C. Giachetti, J. Gallarda, and M. P. Busch. 2005. Dynamics of viremia in early hepatitis C virus infection. Transfusion 45:994-1002. (Pubitemid 40798792)
13. 13. González, V., E. Padilla, M. Diago, M. D. Giménez, R. Sola, L. Matas, S. D. Montoliu, R. M. Morillas, C. Pérez, and R. Planas. 2005. Clinical usefulness of total hepatitis C virus core antigen quantification to monitor the response to treatment with peginterferon alpha-2a plus ribavirin. J. Viral Hepat. 12:481-487. (Pubitemid 41224251)
14. 14. Hinrichsen, H., Y. Benhamou, H. Wedemeyer, M. Reiser, R. E. Sentjens, J. L. Calleja, X. Forns, A. Erhardt, J. Crönlein, R. L. Chaves, C. L. Yong, G. Nehmiz, and G. G. Steinmann. 2004. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127:1347-1355. (Pubitemid 39457761)
15. Iijima, A., E. Tanaka, M. Kobayashi, S. Yagi, M. Mizokami, and K. Kiyosawa. 2000. Relationship between histological prognosis of chronic hepatitis C and amount of hepatitis C virus core protein in serum. J. Gastroenterol. Hepatol. 15:311-319.
16. 16. Kelley, V. A., J. Everett-Kitchens, L. E. Brannon, K. Connor, E. J. Martinez, T. C. Pearson, and F. S. Nolte. 2002. Lack of seronegative hepatitis C virus infections in patients with chronic renal failure. Transplantation 74:1473-1475. (Pubitemid 35379557)
17. Krajden, M., R. Shivji, K. Gunadasa, A. Mak, G. McNabb, M. Friesenhahn, D. Hendricks, and L. Commanor. 2004. Evaluation of the core antigen assay as a second-line supplemental test for diagnosis of active hepatitis C virus infection. J. Clin. Microbiol. 42:4054-4059.
18. Lamarre, D., P. C. Anderson, M. Bailey, P. Beaulieu, G. Bolger, P. Bonneau, M. Bös, D. R. Cameron, M. Cartier, M. G. Cordingley, A. M. Faucher, N. Goudreau, S. H. Kawai, G. Kukolj, L. Lagacé, S. R. LaPlante, H. Narjes, M. A. Poupart, J. Rancourt, R. E. Sentjens, R. St George, B. Simoneau, G. Steinmann, D. Thibeault, Y. S. Tsantrizos, S. M. Weldon, C. L. Yong, and M. Llinàs-Brunet. 2003. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
19. Laperche, S., N. Le Marrec, A. Girault, F. Bouchardeau, A. Servant-Delmas, M. Maniez-Montreuil, P. Gallian, T. Levayer, P. Morel, and N. Simon. 2005. Simultaneous detection of hepatitis C virus (HCV) core antigen and anti-HCV antibodies improves the early detection of HCV infection. J. Clin. Microbiol. 43:3877-3883.
20. Leary, T. P., R. A. Gutierrez, A. S. Muerhoff, L. G. Birkenmeyer, S. M. Desai, and G. J. Dawson. 2006. A chemiluminescent, magnetic particle-based immunoassay for the detection of hepatitis C virus core antigen in human serum or plasma. J. Med. Virol. 78:1436-1440.
21. Lohmann, V., F. Körner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
22. Lunel, F., P. Veillon, I. Fouchard-Hubert, V. Loustaud-Ratti, A. Avergel, C. Silvain, H. Riffert, A. Blanchi, X. Causse, Y. Bacq, and C. Payan. 2003. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen. J. Hepatol. 39:826-833.
23. Maynard, M., P. Pradat, P. Berthillon, G. Picchio, N. Voirin, M. Martinot, and P. Marcellin. 2003. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients response to therapy. J. Viral Hepat. 10:318-323.
24. Mederacke, I., H. Wedemeyer, S. Ciesek, E. Streinmann, R. Raupach, K. Wursthorn, M. P. Manns, and H. L. Tillmann. 2009. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J. Clin. Virol. 46:210-215.
25. Morota, K., R. Fujinami, H. Kinukawa, T. Machida, K. Ohno, H. Saegusa, and K. Takeda. 2009. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J. Virol. Methods 157:8-14.
26. Muerhoff, A. S., L. Jiang, D. O. Shab, R. A. Gutierez, J. Patel, C. Garolis, C. R. Kyrk, G. Leckie, A. Frank, J. L. Stewart, and G. J. Dawson. 2002. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 42:349-356.
27. National Institutes of Health. 2002. NIH consensus statement on management of hepatitis C: 2002. NIH Consens. State. Sci. Statements 19:1-46.
28. Naudin, C., A. Vassault, and A. Truchaud. 1988. Protocol for the study of carry-over on chemistry analysers. Ann. Biol. Clin. 46:215-216.
29. Nick, S., and H. Scheiblauer. 2007. Sensitivities of CE-marked HIV, HCV, and HBsAg assays. J. Med. Virol. 79:S59-S64.
30. Nübling, M., G. Unger, M. Chudy, S. Raia, and J. Löwer. 2002. Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 42:1037-1045.
31. Oniangue-Ndza, C., M. aus dem Siepen, V. Lohmann, M. Wiese, S. Viazov, and M. Roggendorf. 2009. In vitro replicative properties of replicons constructed using sequence variants of the hepatitis C virus strain AD78 that caused a single-source outbreak of hepatitis C. Virus Res. 142:1-9.
32. Passing, H., and W. Bablok. 1983. A new biometrical procedure for testing the equality of measurements from two different analytical methods. J. Clin. Chem. Clin. Biochem. 21:709-720.
33. Pietschmann, T., V. Lohmann, G. Rutter, K. Kurpanck, and R. Bartenschlager. 2001. Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. J. Virol. 75:1252-1264.
34. Pradat, P., M. Maynard, M. Buti, P. Berthillon, G. Picchio, H. L. Tillmann, J. Wiegand, N. Voirin, M. P. Manns, J.-I. Esteban, M. Martinot, P. Marcellin, and C. Trepo. 2004. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. J. Med. Virol. 73:392-396.
35. Richter, S. S. 2002. Laboratory assays for diagnosis and management of hepatitis C virus infection. J. Clin. Microbiol. 40:4407-4412.
36. Ross, R. S., S. O. Viazov, S. Hoffmann, and M. Roggendorf. 2001. Performance characteristics of a transcription-mediated nucleic acid amplification assay for qualitative detection of hepatitis C virus RNA. J. Clin. Lab. Anal. 15:308-313.
37. Ross, R. S., S. Viazov, S. Sarr, S. Hoffmann, A. Kramer, and M. Roggendorf. 2002. Quantification of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J. Virol. Methods 101:159-168.
38. Ross, R. S., S. Viazov, B. Wolters, and M. Roggendorf. 2008. Towards a better resolution of hepatitis C virus (HCV) variants in routine laboratory practice: CLIP sequencing of an HCV core fragment and automated assignment of genotypes and subtypes. J. Virol. Methods 148:25-33.
39. Ross, R. S. 2009. Durch medizinische Behandlungen erworbene Hepatitis C-Infektionen. Krankenhaushygiene up2date 4:29-48.
40. Ross, R. S., S. Viazov, R. Clauberg, B. Wolters, I. Fengler, K. Eveld, R. Scheidhauer, J. Hüsing, Th. Philipp, A. Kribben, and M. Roggendorf. 2009. Lack of de novo hepatitis C virus infections and absence of nosocomial transmissions of GB virus C in a large cohort of German haemodialysis patients. J. Viral Hepat. 16:230-238.
41. Scott, J. D., and D. R. Gretch. 2007. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 297:724-732.
42. Takahashi, M., H. Saito, M. Higashimoto, K. Atsukawa, and H. Ishii. 2005. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J. Clin. Microbiol. 43:186-191.
43. Tanaka, T., J. Y. Lau, M. Mizokami, E. Orioto, R. Tanaka, K. Kiyosawa, K. Yasui, Y. Ohta, A. Hasegawa, S. Tanaka, and H. Kahawa. 1995. Simple fluorescent enzyme immunoassay for detection and quantification of hepatitis C viraemia. J. Hepatol. 23:742-745.
44. Tobler, L. H., S. L. Stramer, S. R. Lee, D. Baggett, D. Wright, D. Hirschkorn, I. Walsh, and M. P. Busch. 2005. Performance of ORTHO® HCV core antigen and trak-C™ assays for detection of viraemia in pre-seroconversion plasma and whole blood donors. Vox Sang. 89:201-207.
45. Vassault, A., D. Grafmeyer, C. Naudin, G. Dumont, M. Bailly, J. Henny, M. F. Gerhardt, and P. Georges. 1986. Protocol for the validation of methods. Ann. Biol. Clin. 44:686-745.
46. World Health Organization. 2002. Global database on blood safety. Report 2001-2002. World Health Organization, Geneva, Switzerland. http://www.who.int/ bloodsafety/GDBS-Report-2001-2002.pdf. Last accessed 18 November 2009.
47. Zanetti, A. R., L. Romanò, M. Brunetto, M. Colombo, G. Bellati, and C. Tackney. 2003. Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapy. J. Med. Virol. 70:27-30.